$CALC News
Last published 2d ago
- 2d agoCALCCalciMedica, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoCALCCalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesGlobeNewswireAuxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both anticipated in mid-2027
- 1w agoCALCCalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireLA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium
- 2mo agoCALCCalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireLA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium
- 2mo agoCALCCalciMedica Announces One-for-Five Reverse Stock SplitGlobeNewswireLA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium
- 3mo agoCALCCalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesGlobeNewswireCompleted private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND
- 3mo agoCALCCalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational EndpointsPR NewswireCalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing calcium release-activated...
- 4mo agoCALCCalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension ProgramPR NewswireCalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium...
- 4mo agoCALCCalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety DataPR NewswireCalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium...
- 6mo agoCALCCalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium...
- 8mo agoCALCCalciMedica Reports 2025 Financial Results and Provides Clinical UpdatesPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium...
- 9mo agoCALCCalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee RecommendationPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium...
- 1y agoCALCCalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial HypertensionPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025PR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™PR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual ConferencePR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory FailurePR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology MeetingPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Announces Presentations at Upcoming Medical MeetingsPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica to Participate in the Jones Healthcare and Technology Innovation ConferencePR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Secures Credit Facility for Up to $32.5 MillionPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT ConferencePR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT ConferencePR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferencePR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Announces Appointment of Dr. Alan Glicklich to Board of DirectorsPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica to Participate in the Piper Sandler 36th Annual Healthcare ConferencePR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 1y agoCALCCalciMedica Announces Presentations at Upcoming Medical MeetingsPR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 1y agoCALCCalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial OfficerPR NewswireCalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica Announces Pricing of Public Offering of Common StockPR NewswireCalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica Announces Proposed Public Offering of Common StockPR NewswireCalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific MeetingPR NewswireCalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)PR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 2y agoCALCCalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific MeetingPR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 2y agoCALCCalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 2y agoCALCCalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica or the Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)PR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica Announces Presentations at Two Upcoming Healthcare Investment ConferencesPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica Set to Join Russell Microcap® IndexPR NewswireCalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
- 2y agoCALCCalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)PR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 2y agoCALCCalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)PR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 2y agoCALCCalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 2y agoCALCCalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024PR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 2y agoCALCCalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute PancreatitisPR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...
- 2y agoCALCCalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate UpdatesPR NewswireCalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated...